• Source: Patritumab deruxtecan

Patritumab deruxtecan (U3-1402/ MK-1022) is an experimental antibody–drug conjugate developed by Merck and Daiichi Sankyo to treat non-small-cell lung cancer.




References

Kata Kunci Pencarian:

• Patritumab deruxtecan
• Deruxtecan
• Trastuzumab deruxtecan
• Patritumab
• Daiichi Sankyo
• Repotrectinib
• Nintedanib
• Dihexa
• Lenvatinib
• Faricimab